Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Peritoneal dialysis solution with dextrose as osmotic agent; removes solutes and water across peritoneal membrane via diffusion and ultrafiltration.
Removes waste products (e.g., urea, creatinine) and excess fluid from the blood through peritoneal dialysis by diffusion and osmosis across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Acute kidney injury requiring peritoneal dialysis
Treatment of acute and chronic renal failureManagement of end-stage renal disease (ESRD)
Intraperitoneal administration: 2 L per exchange, typically 4 exchanges daily (continuous ambulatory peritoneal dialysis). Dextrose 4.25% solution used for ultrafiltration. Dose adjusted based on body size and fluid status.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges daily; dwell time 4-6 hours; concentration selected based on ultrafiltration needs.
None Documented
None Documented
Not applicable as a drug; dextrose is rapidly metabolized; plasma half-life of glucose ~1.5-2 hours; continuous reabsorption in dialysis prevents accumulation.
The terminal half-life of icodextrin (as total icodextrin-derived oligosaccharides) is approximately 5-8 hours after a single dwell, reflecting clearance from the plasma compartment. Clinically, sustained levels can occur with repeated exchanges.
Dextrose absorbed systemically and metabolized via glycolysis; lactate buffer converted to bicarbonate in liver.
Dextrose is metabolized via glycolysis; lactate is converted to bicarbonate in the liver. No significant hepatic metabolism for electrolyte components.
Peritoneal dialysis; effectively removed via peritoneal membrane during dialysis exchanges; systemic absorption of dextrose minimal; elimination primarily through dialysate outflow; renal excretion negligible in anuria.
Delflex-LM with Dextrose 1.5% (icodextrin) is a peritoneal dialysis solution. Icodextrin is metabolized to oligosaccharides and primarily eliminated via the peritoneal cavity during dialysis. Renal excretion is minimal (<1%). The majority of icodextrin and its metabolites are removed with the dialysate effluent.
Not applicable; dextrose does not bind to plasma proteins.
Icodextrin and its metabolites are minimally protein-bound (<5%), primarily to albumin.
Not applicable; dextrose distributes throughout total body water (~0.55 L/kg); dialysate instilled volume is ~2 L per exchange.
The apparent volume of distribution (Vd) for icodextrin-derived oligosaccharides is approximately 0.1-0.2 L/kg, reflecting distribution mainly in the extracellular fluid and limited distribution into cells.
100% via intraperitoneal route as dialysate; dextrose absorbed systemically at ~10-20 g per exchange depending on dwell time and concentration.
Bioavailability: Not applicable for the intraperitoneal route (100% exposure to peritoneal cavity). For systemic absorption, 60-70% of the administered icodextrin dose is absorbed across the peritoneum into the systemic circulation during a dwell, but this is not a standard bioavailability measure.
No dose adjustment needed for impaired kidney function as drug is administered intraperitoneally for dialysis; however, monitor serum electrolytes and fluid balance.
No dose adjustment required for renal impairment as drug is administered intraperitoneally for peritoneal dialysis.
No specific dose adjustment recommended. Caution in severe hepatic impairment due to potential lactic acidosis with dextrose-containing solutions.
No specific pediatric dosing available; use adult dosing with caution and monitor for signs of fluid overload or electrolyte imbalance.
Intraperitoneal: 30-40 mL/kg per exchange, up to 1 L per exchange depending on body size; frequency as needed for dialysis. Dextrose concentration tailored to ultrafiltration needs.
Individualized based on body weight: typical starting volume 30-40 mL/kg per exchange, 4-5 exchanges daily; adjust to achieve adequate ultrafiltration and solute clearance.
Start with lower volumes (e.g., 1.5-2 L per exchange) and monitor for fluid overload and glucose intolerance. Use lowest effective dextrose concentration to minimize hyperglycemia.
Use same dosing as younger adults; monitor fluid and electrolyte status closely due to increased risk of fluid overload and electrolyte disturbances.
Not for intravenous use.
Not for intravenous use. Use only for intraperitoneal administration.
["Monitor serum electrolytes, glucose, and fluid balance","Risk of peritonitis with catheter use","Hypokalemia or hyperglycemia possible","Not for IV administration"]
["Monitor for peritonitis, electrolyte imbalances, and fluid overload","Use with caution in patients with severe hyperglycemia or lactic acidosis","Mechanical complications (e.g., catheter malfunction, leakage) may occur"]
["Pre-existing severe hyperglycemia","Hypersensitivity to any component","Documented loss of peritoneal function","Abdominal conditions compromising dialysis (e.g., recent surgery, adhesions)"]
["Severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions or fibrosis compromising membrane function","Active intra-abdominal infection or peritonitis","Pre-existing severe lactic acidosis","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No specific food interactions. However, dietary restrictions typically include limiting sodium, potassium, phosphorus, and fluid intake as recommended by the nephrologist. Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) and high-phosphorus foods (e.g., dairy, nuts, colas) to prevent electrolyte imbalances. Consult a renal dietitian for personalized meal planning.
["Avoid foods high in potassium (e.g., bananas, oranges, potatoes, tomatoes) unless dietary potassium is restricted per renal diet.","Limit intake of phosphorus-rich foods (e.g., dairy, nuts, beans) to manage hyperphosphatemia.","Restrict sodium intake to control fluid retention and blood pressure as advised by renal diet.","Maintain adequate protein intake as prescribed, typically 1.2-1.5 g/kg/day.","Monitor fluid intake as per individual dry weight and ultrafiltration goals.","Avoid grapefruit juice as it may affect drug metabolism (relevant only if concomitant medications are affected)."]
Delflex w/ Dextrose 4.25% is a peritoneal dialysis solution. No direct fetal risks are expected from the solution itself; however, maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) could affect the fetus. In the first trimester, uncontrolled diabetes may increase the risk of congenital anomalies. In the second and third trimesters, maternal hyperglycemia may lead to fetal macrosomia, neonatal hypoglycemia, and polyhydramnios.
No known teratogenic effects in humans; intraperitoneal administration of dialysis solutions during pregnancy may cause maternal fluid and electrolyte disturbances that secondarily affect the fetus. Use only if clearly needed.
Dextrose and electrolytes from the solution may equilibrate with maternal plasma. Excretion into breast milk is likely minimal and not clinically significant. The M/P ratio is not established; however, the risk to the nursing infant is considered low. Monitoring infant for signs of electrolyte imbalance or hyperglycemia is prudent if maternal serum concentrations are elevated.
Excreted into breast milk in negligible amounts; M/P ratio not established. Compatible with breastfeeding.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics of components. No specific dose adjustments for Delflex w/ Dextrose 4.25% are established; however, frequent monitoring of maternal glucose and electrolytes is advised to adjust dialysis prescription as needed to maintain metabolic control.
No specific dose adjustment recommended; monitor for volume overload and electrolyte imbalances due to increased plasma volume in pregnancy.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% is a peritoneal dialysis solution used in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Monitor for signs of peritonitis, such as cloudy effluent, abdominal pain, and fever. Ensure strict aseptic technique during exchange to prevent infection. The 4.25% dextrose concentration is hypertonic and used for ultrafiltration in fluid overload. Check electrolyte levels regularly, especially potassium and magnesium, as dialysis can alter serum levels. Warm the solution to body temperature before use to improve comfort and dialysis efficiency.
Continuous ambulatory peritoneal dialysis (CAPD) solution; verify glucose concentration (1.5%) and correct patient before use; warm to body temperature prior to instillation to reduce discomfort; check for cloudiness, discoloration, or leaks before administration; monitor effluent for clarity and volume; adjust dwell time based on ultrafiltration needs; use sterile technique for connection and disconnection.
Wash hands thoroughly before handling the dialysis solution or performing exchanges.Use a clean, dry area for all exchanges and keep the catheter site clean and dry.Inspect the solution bag for cloudiness, leaks, or particulate matter before use; do not use if any are present.Do not reuse or refrigerate the solution; store at room temperature and protect from light.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or cloudy effluent immediately.Follow your prescribed exchange schedule exactly to maintain proper fluid and waste removal.
Wash hands thoroughly before handling the solution.Inspect the solution bag for any cloudiness, particles, or leaks before use; do not use if present.Warm the solution to body temperature by placing it on a warmer or using body heat, not in boiling water or microwave.Use strict sterile technique when connecting and disconnecting the solution to prevent infection.Record the volume of effluent drained and report any significant decrease or cloudy appearance to your healthcare provider.Follow the prescribed dwell time and exchange schedule exactly as directed.Do not reuse any of the solution or tubing; all components are for single use only.Store unused bags at room temperature away from direct sunlight and heat.